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Introduction {#sec001}
============

In pregnant women, *Plasmodium falciparum*-infected erythrocytes (IE) express an antigen, VAR2CSA, that participates in the binding of IE to chondroitin sulfate A (CSA) on the syncytiotrophoblast lining the intervillous space of the placenta \[[@pone.0237671.ref001], [@pone.0237671.ref002]\]. The sequestration of IE in placental tissue results in the pathogenesis of placental malaria (PM). PM is an important risk factor for maternal anemia and delivery of low birth weight babies \[[@pone.0237671.ref003], [@pone.0237671.ref004]\], which remains one of the leading causes of mortality and morbidity in neonates and infants in sub-Saharan Africa. Thus, preventing malaria in pregnant women is necessary not only to reduce maternal morbidity but also to minimize the consequence of PM on the health of their offspring. Upscaling of malaria control strategies, particularly effective case management with the use of rapid diagnostic tests, use of intermittent preventive treatment with sulfadoxine-pyrimethamine during pregnancy (IPTp-SP), and insecticide-treated bed nets (ITN), have led to a worldwide reduction of malaria-related morbidity and mortality \[[@pone.0237671.ref005]\]. However, compliance with intervention strategies together with the expanding resistance to anti-malarial drugs and insecticides pose a great challenge. In addition, SP cannot be administered in women during the first trimester of the pregnancy, although *P*. *falciparum* infection is also frequent and harmful during this period \[[@pone.0237671.ref006]\]. The development of an effective vaccine against PM may offer a sustainable solution to protect mothers and their babies from malaria-related morbidity and mortality in endemic areas.

As the major *P*. *falciparum* surface protein that mediates IE accumulation in the placenta \[[@pone.0237671.ref007], [@pone.0237671.ref008]\], leading to inflammation, the VAR2CSA antigen is the main target of protective immunity to PM. In many malaria endemic areas, exposure to malaria is perennial and pregnant women acquire antibodies (Ab) to VAR2CSA over successive pregnancies that improve pregnancy outcomes \[[@pone.0237671.ref009], [@pone.0237671.ref010]\]. Previous studies reported that parasites with a VAR2CSA knock-out gene irreversibly lose the ability to adhere to CSA \[[@pone.0237671.ref011]\], and that Ab to VAR2CSA inhibit IE binding to CSA *in vitro* \[[@pone.0237671.ref012], [@pone.0237671.ref013]\]. This evidence strongly supports VAR2CSA as the leading candidate for a PM vaccine. The rationale for a PM vaccine is to induce immunological memory to the IE with the VAR2CSA phenotype, and elicit an accelerated response upon subsequent *P*. *falciparum* infections. Prior studies reported that high malaria transmission is required for natural acquisition of long-lasting Ab response to PM \[[@pone.0237671.ref014]\]. Thus, any variable that affects the risk for *P*. *falciparum* exposure could influence the magnitude and the quality of Ab response to the potential VAR2CSA-based vaccine. Although SP inhibits folic acid synthesis in malaria parasites, which is required for parasite replication, decreasing thereby the exposure of pregnant women to *P*. *falciparum* antigens, conflicting data exist about the impact of IPT on Ab response to VAR2CSA. In fact, the use of IPTp-SP has resulted in decreased Ab levels to VAR2CSA in some high transmission settings \[[@pone.0237671.ref015], [@pone.0237671.ref016]\], while no impact of the treatment on the Ab response was found in other lower malaria endemic areas \[[@pone.0237671.ref017],[@pone.0237671.ref018]\]. This suggest that the impact of IPT on Ab response to VAR2CSA changes across different geographic conditions.

The eco-epidemiological profile of malaria transmission in Cameroon is very heterogenic and is made of three patterns (Sahelian, soudanian and equatorial), different by their malaria transmission period and entomological indices \[[@pone.0237671.ref019]\]. Within a given pattern, some variation is also observed; for example, in the equatorial pattern where this study was carried out, the transmission increases from the center urban to rural areas. Available data on Ab response to VAR2CSA in Cameroonian women exist only for central urban (low malaria transmission) \[[@pone.0237671.ref020], [@pone.0237671.ref021]\] or rural area (high malaria transmission) \[[@pone.0237671.ref014], [@pone.0237671.ref015], [@pone.0237671.ref022], [@pone.0237671.ref023]\], although these areas are usually separated by a peri-urban or sub-urban area where malaria transmission is intermediate or relatively low. In addition, most of previous studies on Ab response to VAR2CSA in Cameroon were carried out before the IPTp-SP implementation. The present study sought to evaluate the prevalence of anti-VAR2CSA (FV2 and DBL5) Ab and levels of Ab in women at delivery in Etoudi, a peri-urban area in the capital of Yaoundé, Cameroon, that is a relatively low-malaria transmission area, after long-term implementation of IPTp-SP. The results of the study will help to improve the design of future clinical trials in malaria endemic areas, on the efficacy of the potential VAR2CSA-based vaccine against PM.

Materials and methods {#sec002}
=====================

Ethical considerations {#sec003}
----------------------

The study protocol was reviewed and approved by the National Ethics Committee of Cameroon (Ethical Clearance 2013/02/ N° 029/L/CNERSH/SP). Administrative Authorizations were obtained from the Ministry of the Public Health of Cameroon (No D30-392 AAR/MINSANTE/SG/DROS/ CRC/ CEA1) and from Health Centre. Participation in the study was voluntary with written informed consent from each woman. Upon collection, all samples and clinical information about the mother and baby were de-identified. The study was performed following the guidelines and regulations of human clinical research as recommended by the Ministry of the Public Health of Cameroon. Malaria rapid diagnostic test (RDT) was performed for each woman at the time of enrollment and positive results were reported to the physician for prescription of treatment according to the national policy.

Study population and sample collection {#sec004}
--------------------------------------

This cross-sectional study was carried out between 2013 and 2015 at the Marie Reine Health Center in Etoudi, situated in a peri-urban area of Yaoundé, Cameroon. Malaria transmission in this area is relatively low and perennial, peaking in May (during the long-wet season from March to June) and October (during short wet season from September to November). A total of 130 HIV-negative women aged 16 to 39 years were recruited. Information on the mother's health, estimated length of pregnancy, parity, age, use of anti-malarial drugs, IPTp-SP usage, HIV status, and baby birth weight were recorded. Peripheral blood samples were collected in EDTA tubes from women immediately following delivery. A portion of the blood was used to prepare thick and thin smears for microscopy and to measure hemoglobin levels. The remainder was centrifuged and plasma was collected and stored at -80º C for antibody studies. Placental tissues were also collected and a section excised to prepare impression smears and for histology.

Diagnosis of placental malaria and determination of hemoglobin levels {#sec005}
---------------------------------------------------------------------

Thick and thin blood smears, were prepared using Giemsa-Wright stain and read by two skilled microscopists to determine the presence of malaria parasites. In addition, thin film of peripheral blood was used to determine parasite species. Results from blood smears were compared with RDT results obtained at enrollment using the Carestart^TM^HRP2 (Pf) (Access Bio Inc. NJ, USA). Placental sections were fixed in buffered formalin, embedded, stained with hematoxylin-eosin, and examined for IE and malaria pigments. Women were considered PM+ if IE were detected in impression smears of villous tissue and/or in histological sections. Hemoglobin levels in maternal blood were determined using a Coulter Counter (URIT-3300, Europe).

Measurement of antibodies {#sec006}
-------------------------

Plasma IgG Ab levels to VAR2CSA recombinant proteins (FV2 and DBL5) of the FCR3 strain, expressed in Baculovirus-transfected insect cells, were measured using a multi-analyte platform (MAP). The coupling of the recombinant proteins to MagPix microspheres and basic protocol have been described previously \[[@pone.0237671.ref021], [@pone.0237671.ref024], [@pone.0237671.ref025]\]. Briefly, 50 μl of antigen-coupled microspheres (2000 microspheres/antigen) were incubated in a well of a microtiter plate (U-bottom microplate) with 50 μl of plasma diluted to 1:100 in phosphate buffered saline containing 1% bovine serum albumin (PBS 1% BSA) for 1 h at room temperature on a rotating shaker at 500 rpm (Microplate Shaker, Lab-line, Melrose Park, IL, USA). After washing twice with PBS-0.05% Tween 20 and once with PBS-1% BSA, 100 μl of secondary Ab (R-phycoerythrin-conjugated, Affini Pure F(ab′)2 fragment, Goat anti-human IgG Fc fragment specific, Jackson Immunoresearch, West Grove, PA, USA) diluted to 2 μg/ml in PBS-1% BSA was added to each well and incubated on a shaker in the dark for 1 h. Wells were washed and microspheres re-suspended in 100 μl PBS-1% BSA. Plates were analysed immediately using MAGpix *Analyser (MAGpix Technology*, *USA*). The reader was programmed to read a minimum of 100 beads per spectral address, DD Gate 7500--15,000 and 35s timeout. The results were expressed as median fluorescence intensity (MFI). Positive and negative controls were included on each plate to control for plate-to-plate variation. Positive control was a pool of eight Cameroonian multigravidae with high Ab levels to VAR2CSA. Negative controls were plasma from 12 Cameroonian men, age 23 to 30 years of age, living in the study area. The cut-off value for seropositivity was determined based on the mean MFI + 2SD of the male samples.

Statistical analysis {#sec007}
--------------------

Graph Pad Prism 6.0.1 was used for the statistical analyses. Continuous variables are reported as means +/- standard deviations (SD) or medians with interquartile range (IQR). Differences between groups were compared using unpaired t-test for normally distributed continuous data or Mann-Whitney Rank Sum test for non-normal distributed continuous data, while categorical variables were reported as percentages and were compared using Fisher's exact test. P values \<0.05 were considered statistically significant.

Results {#sec008}
=======

Study population {#sec009}
----------------

The characteristics of women in this study are summarized in [Table 1](#pone.0237671.t001){ref-type="table"}. Initially,105 women were enrolled between June 2013 and February 2014, among whom 9 women had PM, providing an estimated prevalence of PM of 8.6% (9/105). Then, between May and June 2014, 25 women were enrolled to collect additional samples from PM+ women. Among the 25 additional women, 17 were confirmed to have PM+, providing a total of 26 PM+ and 104 PM-negative women in the study (total 130 pregnant women) ([Table 1](#pone.0237671.t001){ref-type="table"}). Among the 26 PM+ women, only 80% were peripheral blood-smear positive for malaria. The PM+ women tended to be younger and pauciparous compared to PM- women, but their mean age, gravidity and parity were not significantly different (age \[24.8 vs. 26.5 years, p = 0.13\]; gravidity \[2.6 vs 2.9, p = 0.36\] and parity \[2.1 v 2.5, p = 0.18\]) ([Table 1](#pone.0237671.t001){ref-type="table"}). However, maternal hemoglobin levels and hematocrits were significantly lower in PM+ compared to PM- women (hemoglobin 10.6 vs 12.8 g/dl and hematocrit 31.8 vs 38.7%, with both p values \<0.0001) and the percentage of women with anemia was higher in the PM+ group (57.7% vs 3.9%, p\<0.0001). Among the 26 women with PM, a wide range in placental parasitemia was found (median parasitemia: 2.5% with interquartile range of 0.1% to 7.6%). The mean baby birth weight in PM+ women was significantly lower than that of PM- women (3,060 vs 3,387 g, p = 0.0046); although the percentage of low birth weight babies did not differ significantly between the groups (11.5 vs 3.9%, p = 0.14). The mean number of IPTp-SP doses taken by PM+ women was lower than PM- women (1.6 vs 2.2 doses, p = 0.01) and the proportion of women using bed nets was lower in the PM+ group compared to PM- group (57.7 vs. 77.7%, p = 0.048). A comparison between women who do not use IPT during pregnancy (n = 22) with women who took 3 doses (n = 70) showed that women receiving 3 doses of SP were older (23.5 vs 26.5 years, p = 0.014), had higher hemoglobin levels (11.8 g/dL vs. 12.8, p = 0.0048) and PCV (35.5% vs. 38.6%, p = 0.005), and had fewer cases of placental malaria (31.8% vs. 5.8%, p = 0.0426).

10.1371/journal.pone.0237671.t001

###### Characteristics of the study groups.

![](pone.0237671.t001){#pone.0237671.t001g}

                                                                           PM+ Women (n = 26)    PM- Women (n = 104)   P values[\*](#t001fn001){ref-type="table-fn"}
  ------------------------------------------------------------------------ --------------------- --------------------- -----------------------------------------------
  Age in years (mean ±SD)                                                  24.8 ± 5.2            26.5 ± 5.2            0.1311
  Gravidity (mean ±SD)                                                     2.6 ± 1.7             2.9 ± 1.7             0.3622
  Parity (mean ±SD)                                                        2.1 ± 1.1             2.5 ± 1.3             0.1770
  Maternal hemoglobin in (g/dL) (mean ±SD)                                 10.6 ± 1.5            12.8 ± 1.18           \<0.0001
  Hematocrit (mean % PCV ±SD)                                              31.8 ± 4.9            38.7 ± 3.6            \<0.0001
  Percentage (%) of women with anemia                                      57.7                  3.9                   \<0.0001
  Peripheral parasitemia: IE/μl \[median and 25%-75% IQR\]                 2889 \[177, 66365\]   0                     
  Placental parasitemia (%) \[median and 25%-75%IQR\]                      2.6 \[0.1, 7.6\]      0                     
  Length of gestation (mean weeks ± SD)                                    39.2 ± 2.7            39.9 ± 2.36           0.3769
  Baby birth weight (mean g ± SD)                                          3060 ± 471            3387 ± 526            0.0046
  Percentage (%) of LBW babies                                             11.5                  3.9                   0.1425
  Number of Doses of SP (mean ± SD)                                        1.6 ± 1.2             2.2 ± 1.1             0.0101
  Percentage (%) women using ITNs[\*\*](#t001fn002){ref-type="table-fn"}   57.7                  77.7                  0.0482

\*Analysis by PM status included: Student t test for normally distributed means; Mann Whitney for non-parametric medians (PCV); and Fisher's Exact test for comparisons of proportions.

\*\* Percentage of women who reported using insecticide treated bednets (ITNs). LBW: low birth weight; SP: sulfadoxine-pyrimethamine.

Levels and prevalence of IgG Ab to VAR2CSA in PM+ and PM- women {#sec010}
---------------------------------------------------------------

Ab levels and the percentage of PM+ and PM- women who had Ab toVAR2CSA antigens were investigated ([Fig 1](#pone.0237671.g001){ref-type="fig"}). For the 130 women, Ab levels to FV2 and DBL5 were higher in PM+ women than PM- women (p = 0.0059 and 0.002, respectively) ([Fig 1A and 1B](#pone.0237671.g001){ref-type="fig"}). Furthermore, when Ab levels were evaluated for only those women who were Ab-positive for FV2 and DBL5, Ab levels remained significantly higher in the PM+ than PM- group (p = 0.0019 and 0.0079, respectively) ([Fig 1C](#pone.0237671.g001){ref-type="fig"}). At term, 61.5% and 57.7% of PM+ women had Ab to FV2 and DBL5, respectively; whereas, only about half as many (31.7% and 30.8%) of PM- women had Ab to these antigens ([Table 2](#pone.0237671.t002){ref-type="table"}). Thus, high Ab levels were associated with infection and many women lacked Ab to the VAR2CSA antigens.

![Antibody levels to VAR2CSA (FV2 and DBL5) in PM+ and PM+ women.\
Plasma Ab levels to VAR2CSA were compared in women by PM status using Mann-Whitney Rank Sum test. A and B: IgG levels for all women (n = 130); C: IgG levels for women who were Ab-positive (i.e., had levels higher than the cut-off (n = 49 women for FV2, n = 47 for DBL5); MFI: median fluorescence intensity; IQR: interquartile range; Ab: antibodies; PM: placental malaria. The horizonal dotted lines show the cut-off for Ab-positive, which was 4,483 MFI for FV2 and 3,232 MFI for DBL-5. Horizontal bars represent the group median +/- 25% IQR.](pone.0237671.g001){#pone.0237671.g001}

10.1371/journal.pone.0237671.t002

###### Percentage of women with antibodies to VAR2CSA (FV2 and DBL5) at delivery by PM and gravidity status.

![](pone.0237671.t002){#pone.0237671.t002g}

         PM+             PM-              P value[\*](#t002fn001){ref-type="table-fn"}                                  
  ------ --------------- ---------------- ---------------------------------------------- -------------- --------------- ----------------------------------------------
  FV2    16/26 (61.5%)   33/104 (31.7%)   0.0067                                                                        
  DBL5   15/26 (57.7%)   32/104 (30.8%)   0.0131                                                                        
         Pauci           MG               P value[\*](#t002fn001){ref-type="table-fn"}   Pauci          MG              P value[\*](#t002fn001){ref-type="table-fn"}
  FV2    9/17 (52.9%)    7/9 (77.8%)      0.3989                                         6/48 (12.5%)   27/56 (48.2%)   0.0001
  DBL5   8/17 (47.1%)    7/9 (77.8%)      0.2167                                         7/48 (14.6%)   25/56 (44.6%)   0.0003

\*Fisher exact test was used for comparison between paucigravidae and multigravidae. The results are presented as percentage. The cut-off for Ab-positive was 4,483 MFI for FV2 and 3,232 MFI for DBL5. Pauci: paucigravidae; MG: multigravidae

Levels and prevalence of IgG Ab to VAR2CSA in women by gravidity status {#sec011}
-----------------------------------------------------------------------

Among PM+ women, the levels of Ab to FV2 and DBL5 did not differ significantly between paucigravid and multigravid women (median: FV2: 10,459 vs 21,078 MFI p = 0.19; DBL5: 3,030 vs 24,450 MFI p = 0.10 ([Fig 2](#pone.0237671.g002){ref-type="fig"}). In addition, there was no difference in the prevalence of Ab to FV2 (52.9% vs 77.8%, p = 0.40) or DBL5 (47.1% vs 77.8% p = 0.22). However, there was a significant difference among PM- women, with multigravidae (MG) having significant higher median Ab levels to FV2 and DBL5 (3,240 and 2,333 MFI) than paucigravidae (1,330 and 1,261 MFI respectively) (both p values ≤0.0001). Similarly, the percentage of PM- MG women having Ab to FV2 and DBL5 (48.2% and 44.6%) was significantly higher than that of paucigaviadae (12.5% and 14.6%, respectively) (p = 0.0001 and 0.0003, respectively) ([Table 2](#pone.0237671.t002){ref-type="table"}).

![Antibody levels to VAR2CSA (FV2 and DBL5) in paucigravid and multigravid women.\
Plasma levels of Ab to VAR2CSA were compared between paucigravidae and multigravidae using the Mann-Whitney Rank Sum test. A and B: IgG Ab levels for all women (n = 130); C: IgG levels for women with Ab levels higher than the cut-off (i.e., results for only Ab+ women) (n = 49 women for FV2, n = 47 women for DBL5); MFI: median fluorescent intensity; IQR: interquartile range; Pauci: Paucigravid women; MG: Multigravid women; Ab: antibody; Cut-off for Ab-positive was 4,483 MFI for FV2 and 3,232 MFI for DBL5. Horizontal bars represent the group median +/- 25% IQR.](pone.0237671.g002){#pone.0237671.g002}

Influence of use of SP on Ab levels and prevalence {#sec012}
--------------------------------------------------

The impact of IPTp-SP on Ab levels and percentage of women who were sero-positive at delivery for FV2 and DBL5 was assessed ([Fig 3](#pone.0237671.g003){ref-type="fig"}, [Table 3](#pone.0237671.t003){ref-type="table"}). The use of two or three doses of SP did not significantly impact either the percentage of women with Ab to FV2 and DBL5 or Ab levels in Ab-positive women compared to women not taking or taking only one dose of SP.

![Influence of number of doses of SP on Ab levels to VAR2CSA (FV2 and DBL5) at delivery.\
Mann-Whitney Rank Sum test was used to compare median plasma Ab levels to VAR2CSA between groups. A and B: IgG levels for all women (n = 130). C and D: IgG levels for Ab-positive women (n = 45 women for FV2, n = 47 women for DBL5). MFI: median fluorescence intensity; IQR: interquartile range; Ab: antibody; The cut-off for Ab-positivity was 4,483 MFI for FV2 and 3,232 MFI for DBL5. Horizontal bars represent the group median +/- 25% IQR.](pone.0237671.g003){#pone.0237671.g003}

10.1371/journal.pone.0237671.t003

###### Percentage of women with antibodies to VAR2CSA (FV2 and DBL5 FCR3) at delivery by use of IPTp-SP.

![](pone.0237671.t003){#pone.0237671.t003g}

          0--1 Dose       2--3 Doses      p value[\*](#t003fn001){ref-type="table-fn"}
  ------- --------------- --------------- ----------------------------------------------
  FV2     10/36 (27.8%)   35/94 (37.2%)   0.4104
  DBL-5   10/36 (27.8%)   37/94 (39.4%)   0.3377

\*Comparison between women who received 0--1 dose and 2--3 doses of SP. The results are presented as percentage. Fisher exact test was used. The cut-off for Ab-positivity was 4,483 MFI for FV2 and 3,232 MFI for DBL5.

Discussion {#sec013}
==========

The present study sought to evaluate Ab prevalence and levels to VAR2CSA (FV2 and DBL5) in women at delivery in Etoudi, a peri-urban area in Yaoundé, Cameroon, that is a relatively low-malaria transmission area, after long-term implementation of IPTp-SP. The transmission of malaria is decreasing in many parts of the world and Ab levels to *P*. *falciparum* antigens may decline in the absence of boosting. Studies have reported that Ab levels to VAR2CSA decreased in high transmission areas \[[@pone.0237671.ref015], [@pone.0237671.ref016]\] or remained unchanged in lower transmission areas in women receiving IPT \[[@pone.0237671.ref017], [@pone.0237671.ref018]\]. Thus, investigations in areas with different malaria transmission intensities are required, because the impact of IPT on the Ab responses changes under different geographic conditions.

IPTp-SP has been implemented in Cameroon since 2004 and the coverage rate of IPTp-SP (at least one dose of SP during pregnancy) is currently estimated at 30% in the rural areas and 70% in the urban areas \[[@pone.0237671.ref025]\]. In the current study, 83% of women took at least one dose of IPTp-SP and 74% reported sleeping under a bed net during pregnancy, suggesting high compliance to these preventive measures. Although it is recommended that all Cameroonian women take at least three doses of SP during pregnancy (starting from the second trimester) \[[@pone.0237671.ref026]\], SP is not free in some private health centers and is not prescribed for women taking some drugs, such as cotrimoxazole. These reasons help explain why about 17% of women in this study did not take SP. Compared to women who do not use IPTp-SP during pregnancy, women taking 3 doses were older, had higher hemoglobin levels and PCV, and had fewer cases of PM. Thus, IPT-SP is having a positive impact in Etoudi. This finding is in line with that of a previous study that have reported an association between IPTp-SP usage and decrease of cases of PM in Cameroonian women \[[@pone.0237671.ref015]\]. However, a small proportion (8/70) of women who took the complete three-dose regimen of IPTp-SP still had *P*. *falciparum* infection. This could be due to the presence of resistance to the drug as it has been reported in Cameroon \[[@pone.0237671.ref027]\], differences in the duration of SP half-life in the individual, or timing of treatment. Encouraging pregnant women and clinicians to adhere to the new WHO policy that recommends the use of SP at each prenatal visit after the first trimester \[[@pone.0237671.ref028]\] could further reduce the prevalence of placental malaria.

As expected, few women had Ab to FV2 and DBL5 in this low transmission area, where IPTp-SP intervention has been used for \>10 years. In fact, among the 104 PM- women at delivery only 31.7% and 30.8% had Ab to FV2 and DBL5 respectively, and only 12.5% of paucigravidae and 48% of MG had Ab to FV2 ([Table 2](#pone.0237671.t002){ref-type="table"}). Although pre-IPT Ab prevalence in Etoudi is unknown, Ab prevalence to FV2 in PM- women living in Yaoundé prior to implementation was 24.3% in pauci- and 40.1% in MG \[[@pone.0237671.ref020]\]. Thus, with decreased transmission and extended use of IPT, today fewer women have Ab to FV2 during their first two pregnancies, but Ab prevalence is similar in MG. Since the Ab response was higher in PM+ than PM- women ([Fig 1](#pone.0237671.g001){ref-type="fig"}), Ab to these pregnancy-associated antigens are a marker of infection and not protection. One of the more relevant findings of this study is that Ab prevalence was similar in paucigravidae (1 to 2 pregnancies) and MG (3 or more pregnancies) who have PM to FV2 (52.9% vs 77.8%, p = 0.40) or DBL5 (47.1% vs 77.8% p = 0.22). Thus, even when parasites were sequestered in the placenta, many women lacked Ab to VAR2CSA at delivery. In addition, the difference in Ab levels between pauci- and multi-gravidae was not significantly different (median: FV2: 10,459 vs 21,078 MFI p = 0.19; DBL5: 3,030 vs 24,450 MFI p = 0.10, respectively ([Fig 2](#pone.0237671.g002){ref-type="fig"}). The combined data suggest that some MG women had not become infected during previous pregnancies due to low malaria transmission and the use of IPT-SP and produced either a primary or weak secondary Ab response during the current pregnancy; whereas, other MG produced higher levels of Ab ([Fig 2](#pone.0237671.g002){ref-type="fig"}), although the difference was neither statistically significant nor robust enough to eliminate IE sequestered from the placenta. The absence of Ab in low transmission areas suggests that VAR2CSA is not highly immunogenic and that i) repeated exposure is needed to induce a strong Ab response to VAR2CSA and/or ii) Ab to other malarial antigens help control parasitemia \[[@pone.0237671.ref020]\]. Since few women in Etoudi have high Ab levels to VAR2CSA, a VAR2CSA vaccine would be beneficial not only to primigravidae, but to multigravidae as well.

In this study, over 38% of women who had PM failed to produce Ab to FV2 and DBL5 ([Table 2](#pone.0237671.t002){ref-type="table"}). Since IE were sequestered in the placenta, the question becomes, why didn't they produce detectable Ab to VAR2CSA? Several explanations seem feasible. First, some of the women may have become infected too close to delivery to have produced Ab. However, since malaria transmission was perennial and over one-third of PM+ women lacked Ab, one would expect most women to be infected prior to the last 2--3 weeks of pregnancy. Second, the SP may have reduced or eliminated malarial parasites to levels below that required to induce an immune response. However, since Ab levels in women receiving 0--1 doses versus 2--3 doses had similar Ab levels ([Fig 3](#pone.0237671.g003){ref-type="fig"}) and prevalence ([Table 3](#pone.0237671.t003){ref-type="table"}), this explanation does not entirely answer the question. Thirdly, IPTp-SP could result in very low, persistent levels of VAR2CSA that induce T-reg responses. Fourthly, in this study, only the FcR3 allelic form of VAR2CSA was used. Since VAR2CSA is a polymporphic protein \[[@pone.0237671.ref029]\], it is possible that women have Ab to variants of FV2 or DBL5 that were not detected. Finally, multiple infections might be required to induce a sustainable immune response to VAR2CSA. In support of this possibility are data from a study conducted in Yaoundé (low transmission) and Ngali II (high transmission) \[[@pone.0237671.ref022]\]. In a cohort of women who are either slide- or PCR-positive for *P*. *falciparum* before 6 months of pregnancy, at delivery only \~32% primi- and 40% multi-gravidae in Yaoundé compared to 80% of primi- and \>90% of multi-gravidae in Ngali II had Ab to FV2 at delivery \[[@pone.0237671.ref014]\]. Thus, multiple infections during pregnancy may be needed to boost the response, and the level of exposure is not sufficient in lower transmission areas or when IPTp-SP is used. No matter what the explanation, not all women who have PM make Ab to VAR2CSA. Determining why they don't, could be of value for designing a vaccine for preventing PM.

Many questions remain about the impact of IPT-SP on acquisition of immunity to PM. In the current study, PM was diagnosed by detecting infected erythrocytes in the intervillous space of placenta. Thus, some women in the PM- group could have had submicroscopic infections that might have boosted their Ab response \[[@pone.0237671.ref030]\]. Although Ab detected in this study recognized FV2 and DBL5, it is unclear if they are able to block the binding of IE to CSA. VAR2CSA is a polymorphic protein and the FcR3 variant used in this study may not be the predominant strain current circulating in Etoudi. Since functional Ab to placental parasites are variant dependent \[[@pone.0237671.ref031]\], a number of molecular, immunological and epidemiological studies are needed before a complete understanding of the role of VAR2CSA is determined and how IPT-SP alters the natural response to this important antigen.

Conclusion {#sec014}
==========

The results of this study suggest that long-term implementation of IPTp-SP in a relatively low-malaria transmission area results in few women having Ab to VAR2CSA and Ab levels remain low in those with and without PM.

Supporting information {#sec015}
======================
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Click here for additional data file.
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Thank you for submitting your manuscript to PLoS ONE. After careful consideration, we felt that your manuscript requires substantial revision, following which it can possibly be reconsidered, thus governing the decision of a "major revision". As requested by the reviewers, the authors need to address several concerns, particularly related to the study design, methods and results. For example, the study would benefit from an additional interpretation of the data. Study limitation should be included (how about submicroscopic infections). We therefore invite you to submit a revised version of the manuscript paying close attention to the specific points raised by both reviewers.  For your guidance, a copy of the reviewers\' comments was included below

Please submit your revised manuscript by July 10. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at <plosone@plos.org>. When you\'re ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled \'Manuscript\'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

We look forward to receiving your revised manuscript.

Kind regards,

Luzia Helena Carvalho, Ph.D.

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1\. Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at

<https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf> and

<https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

2\. We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For more information on unacceptable data access restrictions, please see <http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions>.

In your revised cover letter, please address the following prompts:

a\) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially sensitive information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

b\) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. For a list of acceptable repositories, please see <http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories>.

We will update your Data Availability statement on your behalf to reflect the information you provide.

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: I enjoyed reading this well-written manuscript examining antibody responses to the pregnancy-specific malaria protein VAR2CSA in women in Cameroon. Understanding more about the impact of intermittent preventive treatment in pregnancy on population levels of antimalarial immunity is important for designing appropriate malaria interventions to achieve malaria elimination.

I have no major concerns with the scientific approach or conclusions drawn from the findings. I would recommend the following minor changes:

Line 60, page 3: Consider changing "efficient" vaccine to "effective" vaccine, but then you use effective twice, so perhaps change to the following, or similar:

"The development of an effective vaccine against PM may offer a sustainable solution to protect mothers and their babies from malaria-related morbidity and mortality in endemic areas".

Line 138-139, page 7: The reference provided (Ref 24; Babakhanyan et al 2016) in turn refers to earlier papers for details on coupling of recombinant proteins to MagPix microspheres, so I would suggest including the reference to these earlier papers.

Line 162, page 8: Change "unpair t-test" to "unpaired t-test". Also provide a general statement, similar to what is included in footnote to table 1, on when t-tests were used and when Mann-Whitney Rank Sum were used (e.g. normal versus nonnormal continuous data)

Line 168-170, page 8: Upon initial reading it was not clear what was meant by "among whom 105 were randomly enrolled between June 2013 and February 2014". Does this mean that a subset of 105 were randomly selected from the total of 130, or that 105 was the number of women who were enrolled between June 2013 and February 2014 (with the remaining 25 enrolled outside this period)?. I continued to read, and this was clarified to some extent at line 171, but the rationale for describing the women in separate groups is not entirely clear.

Line 170, page 8: If the study is cross-sectional (measurements only conducted at a single time point for each woman), I would avoid using the word "cohort" to describe the women, as this implies they were followed up over time. Many people use the word more loosely, but its not strictly correct from an epidemiological perspective.

Line 177, page 8, onwards: In the results text the authors provide P values to indicate differences between PM+ and PM- women across a series of clinical parameters. I would prefer to see some indication of the actual difference in values within the text as well as the table because the p value by itself does not tell you anything about the magnitude (and therefore clinical significance) of the differences.

Table 1: Perhaps change "Percent women with anemia" to "Percentage of women with anemia\" or \"Anemia, n (%)" and "Percent LBW babies" to \"Percentage LBW\" or \"Low birth weight, n (%)". Also, \"Percentage of women using ITNs or \"ITN use, n (%)\" and explain in the footnote or elsewhere how ITN use was defined.

Figure 1, 2, 3: Ensure consistent positioning of labels for median values, p values. Some median values are crossing the horizontal bars so it looks a bit messy.

Line 262-263: To my understanding, rapidly declining immunity in the absence of boosting has not been well characterized, more just inferred, so perhaps add references here or qualify the statement.

Line 285: Change "women having used" to "women who had used"

Reviewer \#2: This paper reports immune response against VAR2CSA among Cameroonian pregnant women after a long-term implementation of intermittent preventive treatment (IPT). The strengths of the study are that it uses a full-length of VAR2CSA, the DBL5e domain of VAR2CSA; which is one of the most immunogenic antigen DBL5e and multi-analyte platform to assess the immune responses against VAR2CSA. The research team is highly skilled to properly address the research aims. The authors diagnose malaria on the population of study by using Giemsa-Wright stained thick and thin blood smears. In addition, they used thin films of peripheral blood to assess parasites species. Antibodies against VAR2CSA levels and frequency were characterized by a multi-analyte platform. Statistical analyses are adequately used and emerging data are interesting. The authors also report a significant adherence of malaria in pregnancy preventive measures including IPT in the region of study. Moreover, firstly, they find that a low number of women attending the clinic had placental malaria. Secondly, they demonstrate that more than 50% of pregnant women with placental malaria (PM) had antibodies against VAR2CSA at delivery. Interestingly, they also show that pregnant women taking 3 doses of ITP-SP displayed higher levels of hemoglobin and low risk of placental infections at delivery. The authors conclude that their data will help to better improve the design of future clinical trials in malaria endemic areas, and the efficacy VAR2CSA-based vaccines against MIP.

The outcomes of this study demonstrate the significant impact of IPT-SP on VAR2CSA antibodies levels and frequency in pregnant women within a unique malaria epidemiological setting as Cameroon. Although, this study makes an important contribution to the field, I still do have major comments that need to be addressed.

Major comments

Comment \#1

One of the major weakness of this study is the lack of a full interpretation of the authors' data. The authors scarcely explain the physiological aspect of their results and how, in a clear and definite way, these data can help in the surveillance of pregnant women health during MIP, the improvement of IPT-SP treatment and the development of a VAR2CSA-based vaccine.

Comment \#2

Lines 45-46

Can the authors rewrite the following sentence?

It's well established that pregnancy specific-infected erythrocytes (IE) express several variable surface antigens (VSA). VSA group is composed of many antigens families including PfEMP1, Stevor and Rifin. VAR2CSA is the best-characterized antigen from PfEMP1 family. Knock-out study has showed that VARCSA is the main antigen but not the unique antigen since, 15 to 20% of CSA-selected IE still bound to CSA after var2csa gene invalidation (Viebig et al., 2007). Moreover, some studies have identified different novel proteins with unknown functions. These proteins have structural motifs suggesting that they may potentially be expressed at the surface of IE and involved in malaria in pregnancy pathogenesis (Fried M et al., 2007; Francis SE et al., 2008; Bertin G et al., 2013).

Comment \#3

Lines 130-131

Various studies have shown the importance of the use of qPCR to diagnose malaria since submicroscopic infections are underestimate in many African regions. The authors shall discuss this as a limitation of their study if they can provide qPCR data of their samples.

Comment \#4

Lines 137-138

Can the authors describe with more clarity, the source of these recombinant proteins: insect cells, bacteria?

Comment \#5

Lines 154

Please add the range of age for the three malaria-naïve Americans and 12 Cameroonian men living in the area of study. Also, do clarify how the cut-off was designed. It is still not very clear whether the 3 American and 12 Cameroonian men were all tested to design the cut-off.

Moreover, Plamodium (P) vivax transmission is growing in many sub-Sahara African regions. Have the authors assessed malaria infections or potential previous P. vivax exposure in Cameroonian men?

Comment \#6

Lines 197-198

The authors report this: "For the 130 women, Ab levels to FV2 and DBL5 were higher in PM+ women than PM- women (p = 0.0064 and 0.0182, respectively) (Fig 1A and B)". Whether these high levels of antibodies against FV2 and DBL5e are either marker of infections or protective antibodies against PM isn't discuss anywhere in the manuscript.

Comment \#7

Figure 1 (A and B): Please plot individual American and Cameroonian men serum/plasma reactivity against FV2 and DBL5e on the graph.

Comment \#8

Line 222-223

Can the authors comment these data?

Minor comments

1- Figures are very fuzzy.

2- The ability to inhibit IE adhesion to CSA is the hallmark of efficient antibodies against VAR2CSA in MIP. The authors did not discuss whether antibodies they have identified in the population of study have functional activity.

3- Line 229: why is the word "about" written in bold?

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: Yes: Julia C Cutts

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Author response to Decision Letter 0

17 Jul 2020

Dear Editor Luzia Helena Carvalho,

We thank you and the two reviewers for evaluating our manuscript: PONE-D-20-13928, entitled \"Antibodies to full-length and the DBL5 domain of VAR2CSA in pregnant women after long-term implementation of intermittent preventive treatment in Etoudi, Cameroon\".

Please find here in our responses to reviewer\'s 1 and 2 comments.

Reviewer \#1

I enjoyed reading this well-written manuscript examining antibody responses to the pregnancy-specific malaria protein VAR2CSA in women in Cameroon. Understanding more about the impact of intermittent preventive treatment in pregnancy on population levels of antimalarial immunity is important for designing appropriate malaria interventions to achieve malaria elimination.

I have no major concerns with the scientific approach or conclusions drawn from the findings. I would recommend the following minor changes:

Query \#1

Line 60, page 3: Consider changing "efficient" vaccine to "effective" vaccine, but then you use effective twice, so perhaps change to the following, or similar:

"The development of an effective vaccine against PM may offer a sustainable solution to protect mothers and their babies from malaria-related morbidity and mortality in endemic areas".

Response \#1. The sentence has been revised as suggested by the Reviewer.

Query \#2

Line 138-139, page 7: The reference provided (Ref 24; Babakhanyan et al 2016) in turn refers to earlier papers for details on coupling of recombinant proteins to MagPix microspheres, so I would suggest including the reference to these earlier papers.

Response \#2. References to the earlier papers (Fouda et al., 2006; Banakhanyan et al., 2014) have been added.

Query \#3

Line 162, page 8: Change "unpair t-test" to "unpaired t-test". Also provide a general statement, similar to what is included in footnote to table 1, on when t-tests were used and when Mann-Whitney Rank Sum were used (e.g. normal versus non-normal continuous data)

Response \#3.In the Statistical analysis section, the text has been changed to read:"Differences between groups were compared using unpaired t-test for normal continuous data or Mann-Whitney Rank Sum test for non-normal continuous data, ...."

Line 168-170, page 8: Upon initial reading it was not clear what was meant by "among whom 105 were randomly enrolled between June 2013 and February 2014". Does this mean that a subset of 105 were randomly selected from the total of 130, or that 105 was the number of women who were enrolled between June 2013 and February 2014 (with the remaining 25 enrolled outside this period)?. I continued to read, and this was clarified to some extent at line 171, but the rationale for describing the women in separate groups is not entirely clear.

Response \#4. The text has been changed for clarification. It now reads: "Initially,105 women were enrolled between June 2013 and February 2014, among whom 9 women had PM, providing an estimated prevalence of PM of 8.6% (9/105). Then, between May and June 2014, 25 women were enrolled to collect additional samples from PM+ women."

Query \#5

Line 170, page 8: If the study is cross-sectional (measurements only conducted at a single time point for each woman), I would avoid using the word "cohort" to describe the women, as this implies they were followed up over time. Many people use the word more loosely, but its not strictly correct from an epidemiological perspective.

Response \#5. The word "cohort" has been deleted.

Query \#6

Line 177, page 8, onwards: In the results text the authors provide P values to indicate differences between PM+ and PM- women across a series of clinical parameters. I would prefer to see some indication of the actual difference in values within the text as well as the table because the p value by itself does not tell you anything about the magnitude (and therefore clinical significance) of the differences.

Response \#6. Values from Table 1 have been added to the text next to the corresponding p values as suggested by the reviewer (although this seems a little redundant).

Query \#7

Table 1: Perhaps change "Percent women with anemia" to "Percentage of women with anemia\" or \"Anemia, n (%)" and "Percent LBW babies" to \"Percentage LBW\" or \"Low birth weight, n (%)". Also, \"Percentage of women using ITNs or \"ITN use, n (%)\" and explain in the footnote or elsewhere how ITN use was defined.

Response \#7. The text in the Table 1 has been changed to "Percentage (%) of women with anemia,\" "Percentage (%) of LBW babies," and \"Percentage (%) of women using ITNs." Additionally, the following text has been added to the Table legend: "\*\* Percentage of women who reported using insecticide treated bed nets (ITNs)."

Query \#8

Figure 1, 2, 3: Ensure consistent positioning of labels for median values, p values. Some median values are crossing the horizontal bars so it looks a bit messy.

Response \#8.Median values have been removed from the figure since they are not necessary and the P values have been repositioned in Figures 1,2,3.

Query \#9

Line 262-263: To my understanding, rapidly declining immunity in the absence of boosting has not been well characterized, more just inferred, so perhaps add references here or qualify the statement.

Response \#9. The sentence has been rewritten as follow: "The transmission of malaria is decreasing in many parts of the world and Ab levels to P. falciparum antigens may decline in the absence of boosting."

Query \#10

Line 285: Change "women having used" to "women who had used"

Response \#10. The change has been made.

Reviewer \#2:

This paper reports immune response against VAR2CSA among Cameroonian pregnant women after a long-term implementation of intermittent preventive treatment (IPT). The strengths of the study are that it uses a full-length of VAR2CSA, the DBL5e domain of VAR2CSA; which is one of the most immunogenic antigen DBL5e and multi-analyte platform to assess the immune responses against VAR2CSA. The research team is highly skilled to properly address the research aims. The authors diagnose malaria on the population of study by using Giemsa-Wright stained thick and thin blood smears. In addition, they used thin films of peripheral blood to assess parasites species. Antibodies against VAR2CSA levels and frequency were characterized by a multi-analyte platform. Statistical analyses are adequately used and emerging data are interesting. The authors also report a significant adherence of malaria in pregnancy preventive measures including IPT in the region of study. Moreover, firstly, they find that a low number of women attending the clinic had placental malaria. Secondly, they demonstrate that more than 50% of pregnant women with placental malaria (PM) had antibodies against VAR2CSA at delivery. Interestingly, they also show that pregnant women taking 3 doses of ITP-SP displayed higher levels of hemoglobin and low risk of placental infections at delivery. The authors conclude that their data will help to better improve the design of future clinical trials in malaria endemic areas, and the efficacy VAR2CSA-based vaccines against MIP.

The outcomes of this study demonstrate the significant impact of IPT-SP on VAR2CSA antibodies levels and frequency in pregnant women within a unique malaria epidemiological setting as Cameroon. Although, this study makes an important contribution to the field, I still do have major comments that need to be addressed.

Major comments

Comment \#1

One of the major weakness of this study is the lack of a full interpretation of the authors' data. The authors scarcely explain the physiological aspect of their results and how, in a clear and definite way, these data can help in the surveillance of pregnant women health during MIP, the improvement of IPT-SP treatment and the development of a VAR2CSA-based vaccine.

Response \#1. The Discussion has been extensively revised to include a more biological and practical interpretation of the results. We now point out that many women, including multigravidae, in the Etoudi area of Yaoundé lack antibodies to VAR2CSA and may remain susceptible to placental malaria. Accordingly, all women, not just primigravidae, would benefit from a VAR2CSA vaccine. A statement was included that if clinicians and pregnant women followed the new WHO recommendation (SP at every prenatal visit) the number of PM cases could be reduced further.

As for using pregnant women for surveillance of malaria, unlike in Mozambique (Fonseca et al. 2019), malaria transmission remainshigh in Cameroon with many children having clinical cases of malaria, so restricting surveillance to pregnant women whose infections are being controlled/ eliminated SP does not seem practical at this time. The most interesting finding of the study is that many women who have PM at delivery don't have Ab to VAR2CSA, including many multigravidae. It is likely some of the multigravidaedid not become infected during previous pregnancies and produced a primary Ab response during the current pregnancy. The absence of Ab in low transmission areas suggests that VAR2CSA is not highly immunogenic and that Ab to other malarial antigens may help control parasitemia (Lloyd et al.,2018). These ideas and well as others (see below) are included in the revised manuscript.

Comment \#2

Lines 45-46

Can the authors rewrite the following sentence?

It's well established that pregnancy specific-infected erythrocytes (IE) express several variable surface antigens (VSA). VSA group is composed of many antigens families including PfEMP1, Stevor and Rifin. VAR2CSA is the best-characterized antigen from PfEMP1 family. Knock-out study has showed that VARCSA is the main antigen but not the unique antigen since, 15 to 20% of CSA-selected IE still bound to CSA after var2csa gene invalidation (Viebig et al., 2007). Moreover, some studies have identified different novel proteins with unknown functions. These proteins have structural motifs suggesting that they may potentially be expressed at the surface of IE and involved in malaria in pregnancy pathogenesis (Fried M et al., 2007; Francis SE et al., 2008; Bertin G et al., 2013).

Response \#2. The sentence has been rewritten: "In pregnant women, Plasmodium falciparum-infected erythrocytes (IE) express an antigen, VAR2CSA, that participates in the binding of IE to chondroitin sulfate A (CSA) on the syncytiotrophoblast lining the intervillous space of the placenta \[1, 2\]." The revised statement states the function of VAR2CA, but doesn't claim it is the only ligand involved. We hope this more accurately related the literature.

Comment \#3

Lines 130-131

Various studies have shown the importance of the use of qPCR to diagnose malaria since submicroscopic infections are underestimate in many African regions. The authors shall discuss this as a limitation of their study if they can provide qPCR data of their samples.

Response \#3. The Reviewer is correct that PCR was not used in this study to detect submicroscopic infections. We have stated this is a limitation in the current study in the Discussion.

Comment \#4

Lines 137-138

Can the authors describe with more clarity, the source of these recombinant proteins: insect cells, bacteria?

Response \#4. The following information has been added."The recombinant proteins were from the FcR3 strain of P. falciparum and expressed in Baculovirus-transfected insect cells."

Comment \#5

Lines 154

Please add the range of age for the three malaria-naïve Americans and 12 Cameroonian men living in the area of study. Also, do clarify how the cut-off was designed. It is still not very clear whether the 3 American and 12 Cameroonian men were all tested to design the cut-off.

Moreover, Plamodium (P) vivax transmission is growing in many sub-Sahara African regions. Have the authors assessed malaria infections or potential previous P. vivax exposure in Cameroonian men?

Response \#5. For clarity, the text has been changed to read: "Negative controls were plasma from 12 Cameroonian men, age 23 to 30 years of age, living in the study area. The cut-off value for seropositivity was determined based on the mean MFI + 2SD of the male samples." FYI: The US controls were only used as traditional plate controls. Since data from US controls were not used to calculate the cut-off, the mention of US controls has been deleted.

As for the question about Pv, we are aware of the cross-reactivity of PvDBP and VAR2CSA (e.g., Mitran et al. 2019; Gnidehou et al., 2019). The male samples used in the study were not tested for Pv by PCR. The only information we have is that i) 20 years ago we tested over 200 individuals in Yaoundé for Pv by PCR and all were negative, ii) Pv has not been detected by microscopy in Yaoundé,iii) there is no clinical evidence of Pv infections, and iv) the few reported PCR-positive individuals for Pv in Cameroon resided in northern/west Cameroon (i.e., not in Yaoundé). Since the male controlsin the study had low MFI to full-length FV2, it seems highly unlikely that Pv had an impact on the current study. But it is something to keep in mind in future studies.

Comment \#6

Lines 197-198

The authors report this: "For the 130 women, Ab levels to FV2 and DBL5 were higher in PM+ women than PM- women (p = 0.0064 and 0.0182, respectively) (Fig 1A and B)". Whether these high levels of antibodies against FV2 and DBL5e are either marker of infections or protective antibodies against PM isn't discuss anywhere in the manuscript.

Response \#6. Lines 203 -204 in the original MS attempted to address this topic: "Thus, high Ab levels were associated with infection and many women lacked Ab to the VAR2CSA antigens." A statement has been added to the Discussion stating that high Ab levels are a marker of infection, not protection.

Comment \#7

Figure 1 (A and B): Please plot individual American and Cameroonian men serum/plasma reactivity against FV2 and DBL5e on the graph.

Response \#7. Data for Cameroonian males has been included on Figure 1. Data for the 3 American samples were not included since they are no longer mentioned in the study.

Comment \#8

Line 222-223

Can the authors comment these data?

Response \#8. Data showed there was no statistically-significant difference between Ab levels to FV2 in pauci- and multi-gravidae (MG) who had placental malaria (PM) (median: FV2 10,459 vs 21,078 MFI, p=0.10). However, the range of the data points is large, i.e., from 300 to 33,000 MFI, and there is no central tendency of the distribution.The most logical interpretationis that some MG women have NOT become infected during previous pregnancies due to low malaria transmission and the use of IPT-SP in previous pregnancies. Thus, although they were MG based on pregnancy status, some of the women produced only a primary Ab response during pregnancy. Thanks for pointing this out. We will include this information in the Discussion.

Minor comments

Quarry \#1

Figures are very fuzzy.

Response \#1. The resolution of figures has been improved. They were converted to tiff files via PACEV2.

Quarry \#2

2- The ability to inhibit IE adhesion to CSA is the hallmark of efficient antibodies against VAR2CSA in MIP. The authors did not discuss whether antibodies they have identified in the population of study have functional activity.

Response \#2.Alas, functional Ab assays, neither inhibition of binding nor phagocytosis, can be conducted in the laboratory in Cameroon. The current study, including the multiplex assay was conducted at the Biotechnology Centre, Cameroon. Thus, we didn't determine if any of the Ab to VAR2CSA detected are able to inhibit binding. Additional studies with a significantly large sample size would be required to assess the influence of IPT-SP on "level of functional Ab" and if functional Ab are associated with improved pregnancy outcomes. A paragraph has been added to the Discussion stating limitations of the study and future needs to do functional studies.

Quarry \#3

3- Line 229: why is the word "about" written in bold?

Response \#3. It was a mistake. It has been corrected

###### 

Submitted filename: Response to Reviewers.docx

###### 

Click here for additional data file.
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Dear Dr. DJONTU,

We're pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you'll receive an e-mail detailing the required amendments. When these have been addressed, you'll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at <http://www.editorialmanager.com/pone/>, click the \'Update My Information\' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they'll be preparing press materials, please inform our press team as soon as possible \-- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

Kind regards,

Luzia Helena Carvalho, Ph.D.

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

Reviewer \#2: All comments have been addressed
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